- Antibiotics developer Motif Bio said the US Food & Drug Administration had granted its request for a meeting to discuss iclaprim for the treatment of acute bacterial skin and skin structure infections.

The so-called type A meeting, to take place 3 May, would allow the company to discuss points raised in the complete response letter it received from the FDA related to its new drug application.

'We are pleased that the FDA has granted our meeting request and that critical personnel from the FDA have been invited to attend the upcoming meeting with our internal and external experts,' chief executive Graham Lumsden said.

'We look forward to a collaborative meeting and to discussing with the agency the best way to move iclaprim towards marketing approval.'

Story provided by